Education
About Us
Working with TipRanks
Follow Us
Aspire Biopharma Holdings (ASBP)
NASDAQ:ASBP
Total Valuation
Aspire Biopharma Holdings has a market cap or net worth of $13.51M. The enterprise value is ―.
Market Cap$13.51M
Enterprise Value―
Share Statistics
Aspire Biopharma Holdings has 138,446,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding138,446,100
Owned by Insiders0.01%
Owned by Institutions1.61%
Financial Efficiency
Aspire Biopharma Holdings’s return on equity (ROE) is 8.14 and return on invested capital (ROIC) is 1130.41%.
Return on Equity (ROE)8.14
Return on Assets (ROA)-84.72
Return on Invested Capital (ROIC)1130.41%
Return on Capital Employed (ROCE)2.01
Revenue Per Employee0.00
Profits Per Employee-6.27M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aspire Biopharma Holdings is ―. Aspire Biopharma Holdings’s PEG ratio is -0.00039.
PE Ratio―
PS Ratio0.00
PB Ratio-61.61
Price to Fair Value-61.61
Price to FCF-357.83
Price to Operating Cash Flow-1.43
PEG Ratio-0.00039
Income Statement
In the last 12 months, Aspire Biopharma Holdings had revenue of 0.00 and earned -12.54M in profits. Earnings per share was -0.26.
Revenue0.00
Gross Profit0.00
Operating Income-3.09M
Pretax Income-12.54M
Net Income-12.54M
EBITDA-11.65M
Earnings Per Share (EPS)-0.26
Cash Flow
In the last 12 months, operating cash flow was -3.52M and capital expenditures -4.00, giving a free cash flow of -3.52M billion.
Operating Cash Flow-3.52M
Free Cash Flow-3.52M
Free Cash Flow per Share-0.03
Dividends & Yields
Aspire Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.32
52-Week Price Change-99.13%
50-Day Moving Average0.20
200-Day Moving Average0.37
Relative Strength Index (RSI)35.94
Average Volume (3m)27.58M
Important Dates
Aspire Biopharma Holdings upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Aspire Biopharma Holdings as a current ratio of 0.09, with Debt / Equity ratio of -75.21%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap0.01
Net Debt to EBITDA-0.11
Interest Coverage Ratio-3.46
Taxes
In the past 12 months, Aspire Biopharma Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate>-0.01
Enterprise Valuation
Aspire Biopharma Holdings EV to EBITDA ratio is -8.26, with an EV/FCF ratio of -362.59.
EV to Sales0.00
EV to EBITDA-8.26
EV to Free Cash Flow-362.59
EV to Operating Cash Flow-362.59
Balance Sheet
Aspire Biopharma Holdings has $1.95M in cash and marketable securities with $8.62M in debt, giving a net cash position of -$6.68M billion.
Cash & Marketable Securities$1.95M
Total Debt$8.62M
Net Cash-$6.68M
Net Cash Per Share-$0.05
Tangible Book Value Per Share-$0.19
Margins
Gross margin is 45.54%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin45.54%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aspire Biopharma Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―